Tag: congestive heart failure

1. The use of loop diuretics in acute decompensated heart failure is commonplace, but clinical practice varies widely with regards to the dosage and administration of therapy. 2. This study found that mode of administration (bolus vs. continuous infusion) and dosage (low vs. high) of loop diuretics had no significant effect...
1. Based on 13 independent risk factors that are available at most emergency department (ED) admissions, the MEESSI-AHF (Multiple Estimation of risk based on the Emergency department Spanish Score In patients with Acute Heart Failure) score was able to accurately predict 30-day mortality in ED patients with AHF, particularly...
1. In this multicenter, randomized controlled study, the use of NT-proBNP levels to guide medical interventions for heart failure with reduced ejection fraction (HF-rEF) was non-superior to care as usual for cardiovascular-related hospitalizations and deaths. 2. Secondary endpoints, such as all-cause mortality, adverse events rates, and target NT-proBNP concentrations were...
1. In patients with congestive heart failure (CHF) and baseline heart rate >70 bpm, ivabradine significantly reduced the risk of heart failure hospitalization and death from heart failure compared to placebo. 2. Compared to those on placebo, patients taking ivabradine experienced significantly higher rates of atrial fibrillation, asymptomatic and symptomatic...
1. Oral iron repletion did not improve exercise capacity as measured by peak oxygen uptake (VO2). 2. There were no significant effects from oral iron repletion on 6-minute walk distance, NT-proBNP levels, or overall health status. Evidence Rating Level: 1 (Excellent) Study Rundown: Iron is a major component of hemoglobin and plays...
1. Metformin use is associated with reduced all-cause mortality in patients with chronic kidney disease, congestive heart failure, or chronic liver disease with hepatic impairment. 2. In this systemic review, fewer heart failure readmissions were observed in patients with CKD or CHF that were treated with metformin. Evidence Rating Level: 1...
1. In this secondary analysis of the PARADIGM-HF trial, amongst patients receiving mineralocorticoid receptor antagonists, rates of severe hyperkalemia (>6.0 mEq/L) were reduced in the group randomized to sacubitril/valsartan as compared to the group receiving enalapril. 2. Overall rates of any hyperkalemia (>5.5 mEq/L or >6.0 mEq/L) were not significantly...
1. Based on a randomized, controlled trial, acute ingestion of caffeine was not pro-arrhythmogenic in chronic systolic heart failure patients during the physical stress of a treadmill test. 2. Increased plasma levels of caffeine also did not increase the risk of arrhythmias in these patients. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. Patients treated with sacubitril-valsartan experienced reduction in cardiovascular morbidity and mortality. 2. Cost effectiveness of sacubitril-valsartan was sensitive to the duration of improved outcomes. Evidence Rating Level: 2 (Good) Study Rundown: Sacubitril-valsartan (Entresto, by Novartis) is a novel medication found to treat heart failure with reduced ejection fraction. Following a randomized,...
1. This double-blinded, randomized controlled study found that liraglutide, a GLP-1 agonist, did no better than placebo in influencing post-hospitalization clinical stability. 2. There was no significant benefit of the drug in a subgroup of patients with type 2 diabetes. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart failure is a leading...